Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,21769548,flow rate,"The final mobile phase was acetonitrile: AcONH(4) (10 mM; pH 5.0) 55:45, v/v, with a flow rate of 0.4 mL min(-1), and excitation and emission wavelengths of 265 and 375 nm, respectively.",Simultaneous detection and quantification of parecoxib and valdecoxib in canine plasma by HPLC with spectrofluorimetric detection: development and validation of a new methodology. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21769548/),[ml] / [min],0.4,2954,DB00580,Valdecoxib
,21769548,recoveries,"The best extraction solvent was cyclohexane:Et(2)O (3:2, v/v) that gave recoveries ranging from 81.1% to 89.1% and from 94.8% to 103.6% for parecoxib and valdecoxib, respectively.",Simultaneous detection and quantification of parecoxib and valdecoxib in canine plasma by HPLC with spectrofluorimetric detection: development and validation of a new methodology. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21769548/),%,81.1,2955,DB00580,Valdecoxib
,21769548,recoveries,"The best extraction solvent was cyclohexane:Et(2)O (3:2, v/v) that gave recoveries ranging from 81.1% to 89.1% and from 94.8% to 103.6% for parecoxib and valdecoxib, respectively.",Simultaneous detection and quantification of parecoxib and valdecoxib in canine plasma by HPLC with spectrofluorimetric detection: development and validation of a new methodology. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21769548/),%,89.1,2956,DB00580,Valdecoxib
,21769548,recoveries,"The best extraction solvent was cyclohexane:Et(2)O (3:2, v/v) that gave recoveries ranging from 81.1% to 89.1% and from 94.8% to 103.6% for parecoxib and valdecoxib, respectively.",Simultaneous detection and quantification of parecoxib and valdecoxib in canine plasma by HPLC with spectrofluorimetric detection: development and validation of a new methodology. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21769548/),%,94.8,2957,DB00580,Valdecoxib
,21769548,recoveries,"The best extraction solvent was cyclohexane:Et(2)O (3:2, v/v) that gave recoveries ranging from 81.1% to 89.1% and from 94.8% to 103.6% for parecoxib and valdecoxib, respectively.",Simultaneous detection and quantification of parecoxib and valdecoxib in canine plasma by HPLC with spectrofluorimetric detection: development and validation of a new methodology. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21769548/),%,103.6,2958,DB00580,Valdecoxib
,32264977,flow rate,The procedure was performed in less than 3 min with a gradient elution pumped at a flow rate of 0.4 ml/min.,Determination of parecoxib and valdecoxib in rat plasma by UPLC-MS/MS and its application to pharmacokinetics studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32264977/),[ml] / [min],0.4,12508,DB00580,Valdecoxib
,25135338,IC50,"The IC50 values of VX for COX-2 and COX-1 were 0.45 and 38.6 µM, respectively.",The pharmacokinetics and in vitro/ex vivo cyclooxygenase selectivity of parecoxib and its active metabolite valdecoxib in cats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25135338/),μM,0.45,59991,DB00580,Valdecoxib
,25135338,IC50,"The IC50 values of VX for COX-2 and COX-1 were 0.45 and 38.6 µM, respectively.",The pharmacokinetics and in vitro/ex vivo cyclooxygenase selectivity of parecoxib and its active metabolite valdecoxib in cats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25135338/),μM,38.6,59992,DB00580,Valdecoxib
,25135338,half-life,PX was rapidly converted to VX with a relatively short half-life of 0.4 h.,The pharmacokinetics and in vitro/ex vivo cyclooxygenase selectivity of parecoxib and its active metabolite valdecoxib in cats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25135338/),h,0.4,59993,DB00580,Valdecoxib
,25135338,peak plasma concentration,VX achieved peak plasma concentration (2.79 ± 1.59 µg/mL) at 7 h following PX injection.,The pharmacokinetics and in vitro/ex vivo cyclooxygenase selectivity of parecoxib and its active metabolite valdecoxib in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25135338/),[μg] / [ml],2.79,59994,DB00580,Valdecoxib
,25135338,mean residence times,"The mean residence times for PX and VX were 0.43 ± 0.15 and 5.94 ± 0.88 h, respectively.",The pharmacokinetics and in vitro/ex vivo cyclooxygenase selectivity of parecoxib and its active metabolite valdecoxib in cats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25135338/),h,0.43,59995,DB00580,Valdecoxib
,25135338,mean residence times,"The mean residence times for PX and VX were 0.43 ± 0.15 and 5.94 ± 0.88 h, respectively.",The pharmacokinetics and in vitro/ex vivo cyclooxygenase selectivity of parecoxib and its active metabolite valdecoxib in cats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25135338/),h,5.94,59996,DB00580,Valdecoxib
,19519192,Bioadhesive force,"Bioadhesive force and tensile strength of the optimized formulation were found to be 75 +/- 4 kg m(-1) S(-2) and more than 2.5 kg/3 cm(2), respectively.",Development of mucoadhesive buccal films for the treatment of oral sub-mucous fibrosis: a preliminary study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19519192/),[kg] / [(s)^2·m],75,89082,DB00580,Valdecoxib
,19519192,tensile strength,"Bioadhesive force and tensile strength of the optimized formulation were found to be 75 +/- 4 kg m(-1) S(-2) and more than 2.5 kg/3 cm(2), respectively.",Development of mucoadhesive buccal films for the treatment of oral sub-mucous fibrosis: a preliminary study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19519192/),[3·kg] / [cm(2],more,89083,DB00580,Valdecoxib
,19519192,tensile strength,"Bioadhesive force and tensile strength of the optimized formulation were found to be 75 +/- 4 kg m(-1) S(-2) and more than 2.5 kg/3 cm(2), respectively.",Development of mucoadhesive buccal films for the treatment of oral sub-mucous fibrosis: a preliminary study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19519192/),[3·kg] / [cm(2],2.5,89084,DB00580,Valdecoxib
,19519192,percent drug content,The percent drug content was 98.5 +/- 1.3%.,Development of mucoadhesive buccal films for the treatment of oral sub-mucous fibrosis: a preliminary study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19519192/),%,98.5,89085,DB00580,Valdecoxib
,19519192,permeation,"The drug permeation through the dialysis sac and pig buccal mucosa was found to be 62.70% and 54.39%, respectively.",Development of mucoadhesive buccal films for the treatment of oral sub-mucous fibrosis: a preliminary study. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19519192/),%,62.70,89086,DB00580,Valdecoxib
,19519192,permeation,"The drug permeation through the dialysis sac and pig buccal mucosa was found to be 62.70% and 54.39%, respectively.",Development of mucoadhesive buccal films for the treatment of oral sub-mucous fibrosis: a preliminary study. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19519192/),%,54.39,89087,DB00580,Valdecoxib
,17920584,IC(50),"CS-706 selectively inhibited COX-2 in a human whole blood assay with an IC(50) of 0.31 microM, compared with an IC(50) of 2.2 microM for COX-1.","Preclinical pharmacology profile of CS-706, a novel cyclooxygenase-2 selective inhibitor, with potent antinociceptive and anti-inflammatory effects. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17920584/),μM,0.31,94872,DB00580,Valdecoxib
,17920584,IC(50),"CS-706 selectively inhibited COX-2 in a human whole blood assay with an IC(50) of 0.31 microM, compared with an IC(50) of 2.2 microM for COX-1.","Preclinical pharmacology profile of CS-706, a novel cyclooxygenase-2 selective inhibitor, with potent antinociceptive and anti-inflammatory effects. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17920584/),μM,2.2,94873,DB00580,Valdecoxib
,17920584,ID(50),"In an adjuvant-induced arthritic model in rats, CS-706 suppressed foot swelling prophylactically with an ID(50) of 0.10 mg/kg/day, and decreased foot swelling in the established arthritis therapeutically in a dose range of 0.040 to 1.0 mg/kg/day.","Preclinical pharmacology profile of CS-706, a novel cyclooxygenase-2 selective inhibitor, with potent antinociceptive and anti-inflammatory effects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17920584/),[mg] / [d·kg],0.10,94874,DB00580,Valdecoxib
,16013036,flow rate,The chromatographic separation was achieved by gradient elution consisting of 0.05 M formic acid (pH 3)-acetonitrile-methanol-water at a flow rate of 1.0 mL/min.,"Simultaneous quantitation of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide and celecoxib in plasma by high-performance liquid chromatography with UV detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16013036/),[ml] / [min],1.0,105998,DB00580,Valdecoxib
,16013036,Nominal retention times,"Nominal retention times of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide, IS and celecoxib were 15.63, 17.20, 21.66, 24.95, 26.27, 30.24 and 32.22 min, respectively.","Simultaneous quantitation of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide and celecoxib in plasma by high-performance liquid chromatography with UV detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16013036/),min,15.63,105999,DB00580,Valdecoxib
,16013036,Nominal retention times,"Nominal retention times of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide, IS and celecoxib were 15.63, 17.20, 21.66, 24.95, 26.27, 30.24 and 32.22 min, respectively.","Simultaneous quantitation of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide and celecoxib in plasma by high-performance liquid chromatography with UV detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16013036/),min,17.20,106000,DB00580,Valdecoxib
,16013036,Nominal retention times,"Nominal retention times of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide, IS and celecoxib were 15.63, 17.20, 21.66, 24.95, 26.27, 30.24 and 32.22 min, respectively.","Simultaneous quantitation of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide and celecoxib in plasma by high-performance liquid chromatography with UV detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16013036/),min,21.66,106001,DB00580,Valdecoxib
,16013036,Nominal retention times,"Nominal retention times of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide, IS and celecoxib were 15.63, 17.20, 21.66, 24.95, 26.27, 30.24 and 32.22 min, respectively.","Simultaneous quantitation of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide and celecoxib in plasma by high-performance liquid chromatography with UV detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16013036/),min,24.95,106002,DB00580,Valdecoxib
,16013036,Nominal retention times,"Nominal retention times of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide, IS and celecoxib were 15.63, 17.20, 21.66, 24.95, 26.27, 30.24 and 32.22 min, respectively.","Simultaneous quantitation of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide and celecoxib in plasma by high-performance liquid chromatography with UV detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16013036/),min,26.27,106003,DB00580,Valdecoxib
,16013036,Nominal retention times,"Nominal retention times of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide, IS and celecoxib were 15.63, 17.20, 21.66, 24.95, 26.27, 30.24 and 32.22 min, respectively.","Simultaneous quantitation of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide and celecoxib in plasma by high-performance liquid chromatography with UV detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16013036/),min,30.24,106004,DB00580,Valdecoxib
,16013036,Nominal retention times,"Nominal retention times of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide, IS and celecoxib were 15.63, 17.20, 21.66, 24.95, 26.27, 30.24 and 32.22 min, respectively.","Simultaneous quantitation of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide and celecoxib in plasma by high-performance liquid chromatography with UV detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16013036/),min,32.22,106005,DB00580,Valdecoxib
>,16013036,Absolute recovery,Absolute recovery was >83% from human plasma for all the analytes and IS.,"Simultaneous quantitation of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide and celecoxib in plasma by high-performance liquid chromatography with UV detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16013036/),%,83,106006,DB00580,Valdecoxib
,18254142,total chromatographic run time,"The total chromatographic run time was 2.0 min and the elution of ZFK and IS occurred at approximately 1.11 and 1.58 min, respectively.","Development and validation of a sensitive LC-MS/MS method with electrospray ionization for quantitation of zafirlukast, a selective leukotriene antagonist in human plasma: application to a clinical pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18254142/),min,2.0,126277,DB00580,Valdecoxib
,18254142,ion transitions,The MS/MS ion transitions monitored were 574.2 --> 462.1 for ZFK and 313.3 --> 118.1 for IS.,"Development and validation of a sensitive LC-MS/MS method with electrospray ionization for quantitation of zafirlukast, a selective leukotriene antagonist in human plasma: application to a clinical pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18254142/),,574.2,126278,DB00580,Valdecoxib
,18254142,ion transitions,The MS/MS ion transitions monitored were 574.2 --> 462.1 for ZFK and 313.3 --> 118.1 for IS.,"Development and validation of a sensitive LC-MS/MS method with electrospray ionization for quantitation of zafirlukast, a selective leukotriene antagonist in human plasma: application to a clinical pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18254142/),,462.1,126279,DB00580,Valdecoxib
,18254142,ion transitions,The MS/MS ion transitions monitored were 574.2 --> 462.1 for ZFK and 313.3 --> 118.1 for IS.,"Development and validation of a sensitive LC-MS/MS method with electrospray ionization for quantitation of zafirlukast, a selective leukotriene antagonist in human plasma: application to a clinical pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18254142/),,313.3,126280,DB00580,Valdecoxib
,18254142,ion transitions,The MS/MS ion transitions monitored were 574.2 --> 462.1 for ZFK and 313.3 --> 118.1 for IS.,"Development and validation of a sensitive LC-MS/MS method with electrospray ionization for quantitation of zafirlukast, a selective leukotriene antagonist in human plasma: application to a clinical pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18254142/),,118.1,126281,DB00580,Valdecoxib
,32832543,flow rate,"The plasma was precipitated by acetonitrile, and the two analytes were separated on an Acquity UPLC BEH C18 column (2.1 mm × 50 mm, 1.7 μm); the mobile phase was acetonitrile and 0.1% formic acid with gradient mode, and the flow rate was 0.4 mL/min.",Effects of Dexmedetomidine on the Pharmacokinetics of Parecoxib and Its Metabolite Valdecoxib in Beagles by UPLC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32832543/),[ml] / [min],0.4,138190,DB00580,Valdecoxib
,32832543,m/,"In the negative ion mode, the two analytes and internal standard (IS) were monitored by multiple reaction monitoring (MRM), and the mass transition pairs were as follows: m/z 369.1 → 119.1 for parecoxib, m/z 313.0 → 118.0 for valdecoxib, and m/z 380.0 → 316.0 for celecoxib (IS).",Effects of Dexmedetomidine on the Pharmacokinetics of Parecoxib and Its Metabolite Valdecoxib in Beagles by UPLC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32832543/),,369.1,138191,DB00580,Valdecoxib
,32832543,m/z,"In the negative ion mode, the two analytes and internal standard (IS) were monitored by multiple reaction monitoring (MRM), and the mass transition pairs were as follows: m/z 369.1 → 119.1 for parecoxib, m/z 313.0 → 118.0 for valdecoxib, and m/z 380.0 → 316.0 for celecoxib (IS).",Effects of Dexmedetomidine on the Pharmacokinetics of Parecoxib and Its Metabolite Valdecoxib in Beagles by UPLC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32832543/),,313.0,138192,DB00580,Valdecoxib
,32832543,m/z,"In the negative ion mode, the two analytes and internal standard (IS) were monitored by multiple reaction monitoring (MRM), and the mass transition pairs were as follows: m/z 369.1 → 119.1 for parecoxib, m/z 313.0 → 118.0 for valdecoxib, and m/z 380.0 → 316.0 for celecoxib (IS).",Effects of Dexmedetomidine on the Pharmacokinetics of Parecoxib and Its Metabolite Valdecoxib in Beagles by UPLC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32832543/),,118.0,138193,DB00580,Valdecoxib
,32832543,m/z,"In the negative ion mode, the two analytes and internal standard (IS) were monitored by multiple reaction monitoring (MRM), and the mass transition pairs were as follows: m/z 369.1 → 119.1 for parecoxib, m/z 313.0 → 118.0 for valdecoxib, and m/z 380.0 → 316.0 for celecoxib (IS).",Effects of Dexmedetomidine on the Pharmacokinetics of Parecoxib and Its Metabolite Valdecoxib in Beagles by UPLC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32832543/),,380.0,138194,DB00580,Valdecoxib
,32832543,m/z,"In the negative ion mode, the two analytes and internal standard (IS) were monitored by multiple reaction monitoring (MRM), and the mass transition pairs were as follows: m/z 369.1 → 119.1 for parecoxib, m/z 313.0 → 118.0 for valdecoxib, and m/z 380.0 → 316.0 for celecoxib (IS).",Effects of Dexmedetomidine on the Pharmacokinetics of Parecoxib and Its Metabolite Valdecoxib in Beagles by UPLC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32832543/),,316.0,138195,DB00580,Valdecoxib
,32832543,C max,"C max of parecoxib in group A and group B was 2148.59 ± 406.13 ng/mL and 2100.49 ± 356.94 ng/mL, t 1/2 was 0.85 ± 0.36 h and 0.85 ± 0.36 h, and AUC(0-t) was 2429.96 ± 323.22 ng·h/mL and 2506.38 ± 544.83 ng·h/mL, respectively.",Effects of Dexmedetomidine on the Pharmacokinetics of Parecoxib and Its Metabolite Valdecoxib in Beagles by UPLC-MS/MS. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32832543/),[ng] / [ml],2148.59,138196,DB00580,Valdecoxib
,32832543,C max,"C max of parecoxib in group A and group B was 2148.59 ± 406.13 ng/mL and 2100.49 ± 356.94 ng/mL, t 1/2 was 0.85 ± 0.36 h and 0.85 ± 0.36 h, and AUC(0-t) was 2429.96 ± 323.22 ng·h/mL and 2506.38 ± 544.83 ng·h/mL, respectively.",Effects of Dexmedetomidine on the Pharmacokinetics of Parecoxib and Its Metabolite Valdecoxib in Beagles by UPLC-MS/MS. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32832543/),[ng] / [ml],2100.49,138197,DB00580,Valdecoxib
,32832543,t 1/2,"C max of parecoxib in group A and group B was 2148.59 ± 406.13 ng/mL and 2100.49 ± 356.94 ng/mL, t 1/2 was 0.85 ± 0.36 h and 0.85 ± 0.36 h, and AUC(0-t) was 2429.96 ± 323.22 ng·h/mL and 2506.38 ± 544.83 ng·h/mL, respectively.",Effects of Dexmedetomidine on the Pharmacokinetics of Parecoxib and Its Metabolite Valdecoxib in Beagles by UPLC-MS/MS. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32832543/),h,0.85,138198,DB00580,Valdecoxib
,32832543,AUC(0-t),"C max of parecoxib in group A and group B was 2148.59 ± 406.13 ng/mL and 2100.49 ± 356.94 ng/mL, t 1/2 was 0.85 ± 0.36 h and 0.85 ± 0.36 h, and AUC(0-t) was 2429.96 ± 323.22 ng·h/mL and 2506.38 ± 544.83 ng·h/mL, respectively.",Effects of Dexmedetomidine on the Pharmacokinetics of Parecoxib and Its Metabolite Valdecoxib in Beagles by UPLC-MS/MS. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32832543/),[h·ng] / [ml],2429.96,138199,DB00580,Valdecoxib
,32832543,AUC(0-t),"C max of parecoxib in group A and group B was 2148.59 ± 406.13 ng/mL and 2100.49 ± 356.94 ng/mL, t 1/2 was 0.85 ± 0.36 h and 0.85 ± 0.36 h, and AUC(0-t) was 2429.96 ± 323.22 ng·h/mL and 2506.38 ± 544.83 ng·h/mL, respectively.",Effects of Dexmedetomidine on the Pharmacokinetics of Parecoxib and Its Metabolite Valdecoxib in Beagles by UPLC-MS/MS. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32832543/),[h·ng] / [ml],2506.38,138200,DB00580,Valdecoxib
,32832543,C max,"C max of valdecoxib in group A and group B was 2059.15 ± 281.86 ng/mL and 2837.39 ± 276.78 ng/mL, t 1/2 was 2.44 ± 1.55 h and 2.91 ± 1.27 h, and AUC(0-t) was 4971.61 ± 696.56 ng·h/mL and 6770.65 ± 453.25 ng·h/mL, respectively.",Effects of Dexmedetomidine on the Pharmacokinetics of Parecoxib and Its Metabolite Valdecoxib in Beagles by UPLC-MS/MS. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32832543/),[ng] / [ml],2059.15,138201,DB00580,Valdecoxib
,32832543,C max,"C max of valdecoxib in group A and group B was 2059.15 ± 281.86 ng/mL and 2837.39 ± 276.78 ng/mL, t 1/2 was 2.44 ± 1.55 h and 2.91 ± 1.27 h, and AUC(0-t) was 4971.61 ± 696.56 ng·h/mL and 6770.65 ± 453.25 ng·h/mL, respectively.",Effects of Dexmedetomidine on the Pharmacokinetics of Parecoxib and Its Metabolite Valdecoxib in Beagles by UPLC-MS/MS. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32832543/),[ng] / [ml],2837.39,138202,DB00580,Valdecoxib
,32832543,t 1/2,"C max of valdecoxib in group A and group B was 2059.15 ± 281.86 ng/mL and 2837.39 ± 276.78 ng/mL, t 1/2 was 2.44 ± 1.55 h and 2.91 ± 1.27 h, and AUC(0-t) was 4971.61 ± 696.56 ng·h/mL and 6770.65 ± 453.25 ng·h/mL, respectively.",Effects of Dexmedetomidine on the Pharmacokinetics of Parecoxib and Its Metabolite Valdecoxib in Beagles by UPLC-MS/MS. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32832543/),h,2.44,138203,DB00580,Valdecoxib
,32832543,t 1/2,"C max of valdecoxib in group A and group B was 2059.15 ± 281.86 ng/mL and 2837.39 ± 276.78 ng/mL, t 1/2 was 2.44 ± 1.55 h and 2.91 ± 1.27 h, and AUC(0-t) was 4971.61 ± 696.56 ng·h/mL and 6770.65 ± 453.25 ng·h/mL, respectively.",Effects of Dexmedetomidine on the Pharmacokinetics of Parecoxib and Its Metabolite Valdecoxib in Beagles by UPLC-MS/MS. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32832543/),h,2.91,138204,DB00580,Valdecoxib
,32832543,AUC(0-t),"C max of valdecoxib in group A and group B was 2059.15 ± 281.86 ng/mL and 2837.39 ± 276.78 ng/mL, t 1/2 was 2.44 ± 1.55 h and 2.91 ± 1.27 h, and AUC(0-t) was 4971.61 ± 696.56 ng·h/mL and 6770.65 ± 453.25 ng·h/mL, respectively.",Effects of Dexmedetomidine on the Pharmacokinetics of Parecoxib and Its Metabolite Valdecoxib in Beagles by UPLC-MS/MS. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32832543/),[h·ng] / [ml],4971.61,138205,DB00580,Valdecoxib
,32832543,AUC(0-t),"C max of valdecoxib in group A and group B was 2059.15 ± 281.86 ng/mL and 2837.39 ± 276.78 ng/mL, t 1/2 was 2.44 ± 1.55 h and 2.91 ± 1.27 h, and AUC(0-t) was 4971.61 ± 696.56 ng·h/mL and 6770.65 ± 453.25 ng·h/mL, respectively.",Effects of Dexmedetomidine on the Pharmacokinetics of Parecoxib and Its Metabolite Valdecoxib in Beagles by UPLC-MS/MS. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32832543/),[h·ng] / [ml],6770.65,138206,DB00580,Valdecoxib
,32832543,t 1/2,"There was no significant change in the pharmacokinetics of parecoxib in groups A and B. C max and AUC(0 - ∞) of valdecoxib in group A were 37.79% and 36.19% higher than those in group B, respectively, and t 1/2 was increased from 2.44 h to 2.91 h.",Effects of Dexmedetomidine on the Pharmacokinetics of Parecoxib and Its Metabolite Valdecoxib in Beagles by UPLC-MS/MS. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32832543/),h,2.44,138207,DB00580,Valdecoxib
,32832543,t 1/2,"There was no significant change in the pharmacokinetics of parecoxib in groups A and B. C max and AUC(0 - ∞) of valdecoxib in group A were 37.79% and 36.19% higher than those in group B, respectively, and t 1/2 was increased from 2.44 h to 2.91 h.",Effects of Dexmedetomidine on the Pharmacokinetics of Parecoxib and Its Metabolite Valdecoxib in Beagles by UPLC-MS/MS. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32832543/),h,2.91,138208,DB00580,Valdecoxib
,32214797,mass,"The mass transfer pairs were m/z 368.97→119.01 for parecoxib, m/z 312.89→118.02 for valdecoxib, and m/z 379.98→316.02 for celecoxib (internal standard, IS).",Simultaneous Determination of Parecoxib and Its Metabolite Valdecoxib Concentrations in Beagle Plasma by UPLC-MS/MS and Application for Pharmacokinetics Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32214797/),,368.97,147212,DB00580,Valdecoxib
,32214797,m/z,"The mass transfer pairs were m/z 368.97→119.01 for parecoxib, m/z 312.89→118.02 for valdecoxib, and m/z 379.98→316.02 for celecoxib (internal standard, IS).",Simultaneous Determination of Parecoxib and Its Metabolite Valdecoxib Concentrations in Beagle Plasma by UPLC-MS/MS and Application for Pharmacokinetics Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32214797/),,368.97,147213,DB00580,Valdecoxib
,32214797,m/z,"The mass transfer pairs were m/z 368.97→119.01 for parecoxib, m/z 312.89→118.02 for valdecoxib, and m/z 379.98→316.02 for celecoxib (internal standard, IS).",Simultaneous Determination of Parecoxib and Its Metabolite Valdecoxib Concentrations in Beagle Plasma by UPLC-MS/MS and Application for Pharmacokinetics Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32214797/),,312.89,147214,DB00580,Valdecoxib
,32214797,m/z,"The mass transfer pairs were m/z 368.97→119.01 for parecoxib, m/z 312.89→118.02 for valdecoxib, and m/z 379.98→316.02 for celecoxib (internal standard, IS).",Simultaneous Determination of Parecoxib and Its Metabolite Valdecoxib Concentrations in Beagle Plasma by UPLC-MS/MS and Application for Pharmacokinetics Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32214797/),,118.02,147215,DB00580,Valdecoxib
,32214797,m/z,"The mass transfer pairs were m/z 368.97→119.01 for parecoxib, m/z 312.89→118.02 for valdecoxib, and m/z 379.98→316.02 for celecoxib (internal standard, IS).",Simultaneous Determination of Parecoxib and Its Metabolite Valdecoxib Concentrations in Beagle Plasma by UPLC-MS/MS and Application for Pharmacokinetics Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32214797/),,379.98,147216,DB00580,Valdecoxib
greater,32214797,recovery,The recovery of parecoxib and valdecoxib was greater than 82.54%.,Simultaneous Determination of Parecoxib and Its Metabolite Valdecoxib Concentrations in Beagle Plasma by UPLC-MS/MS and Application for Pharmacokinetics Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32214797/),%,82.54,147217,DB00580,Valdecoxib
,17687276,IC50 (inhibitory concentration 50),CSF valdecoxib concentration rapidly reached in vitro IC50 (inhibitory concentration 50) (1.57 ng/ml) by 17 min and remained consistently higher thereafter.,Intravenous parecoxib rapidly leads to COX-2 inhibitory concentration of valdecoxib in the central nervous system. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17687276/),[ng] / [ml],1.57,162819,DB00580,Valdecoxib
,16995327,area under the plasma concentration-time curve,No effect of valdecoxib (20 mg/d) or rofecoxib (25 mg/d) were detected on the area under the plasma concentration-time curve of metoprolol (323 +/- 333 to 324 +/- 296 or 309 +/- 256 microg x h/l) or at a higher dose.,Valdecoxib does not interfere with the CYP2D6 substrate metoprolol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16995327/),[h·μg] / [l],323,164280,DB00580,Valdecoxib
,16995327,area under the plasma concentration-time curve,No effect of valdecoxib (20 mg/d) or rofecoxib (25 mg/d) were detected on the area under the plasma concentration-time curve of metoprolol (323 +/- 333 to 324 +/- 296 or 309 +/- 256 microg x h/l) or at a higher dose.,Valdecoxib does not interfere with the CYP2D6 substrate metoprolol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16995327/),[h·μg] / [l],324,164281,DB00580,Valdecoxib
,16995327,area under the plasma concentration-time curve,No effect of valdecoxib (20 mg/d) or rofecoxib (25 mg/d) were detected on the area under the plasma concentration-time curve of metoprolol (323 +/- 333 to 324 +/- 296 or 309 +/- 256 microg x h/l) or at a higher dose.,Valdecoxib does not interfere with the CYP2D6 substrate metoprolol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16995327/),[h·μg] / [l],309,164282,DB00580,Valdecoxib
,27107851,flow rate,The analysis was performed in less than 3min with a flow rate of 0.2mL/min.,Simultaneous determination of parecoxib sodium and its active metabolite valdecoxib in rat plasma by UPLC-MS/MS and its application to a pharmacokinetic study after intravenous and intramuscular administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27107851/),[ml] / [min],0.2,166246,DB00580,Valdecoxib
more,27107851,extraction recoveries,The mean extraction recoveries for all analytes obtained from three concentrations of QC plasma samples were more than 89.0% efficient.,Simultaneous determination of parecoxib sodium and its active metabolite valdecoxib in rat plasma by UPLC-MS/MS and its application to a pharmacokinetic study after intravenous and intramuscular administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27107851/),%·efficient,89.0,166247,DB00580,Valdecoxib
,15473012,Retention times,"Retention times of etoricoxib and valdecoxib were 1.05 and 1.08 min, respectively.",A liquid chromatography-mass spectrometry method for the quantification of both etoricoxib and valdecoxib in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15473012/),min,1.05,167007,DB00580,Valdecoxib
,15473012,Retention times,"Retention times of etoricoxib and valdecoxib were 1.05 and 1.08 min, respectively.",A liquid chromatography-mass spectrometry method for the quantification of both etoricoxib and valdecoxib in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15473012/),min,1.08,167008,DB00580,Valdecoxib
,16599270,flow rate,The mobile phase was a mixture of acetonitrile:water acidified to pH 3.2 with orthophosphoric acid (OPA) (60:40) pumped at room temperature and a flow rate of 1 ml/min.,Determination of valdecoxib in serum using a HPLC-diode array detector and its application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16599270/),[ml] / [min],1,168944,DB00580,Valdecoxib
,16599270,absolute recovery,"The mean absolute recovery value was about 90%, while the intra (n = 5) and inter (n = 5) assay variations were <18%.",Determination of valdecoxib in serum using a HPLC-diode array detector and its application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16599270/),%,90,168945,DB00580,Valdecoxib
<,16599270,absolute recovery,"The mean absolute recovery value was about 90%, while the intra (n = 5) and inter (n = 5) assay variations were <18%.",Determination of valdecoxib in serum using a HPLC-diode array detector and its application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16599270/),%,18,168946,DB00580,Valdecoxib
<,16599270,limit of detection,The limit of detection was < or = 10 ng/ml.,Determination of valdecoxib in serum using a HPLC-diode array detector and its application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16599270/),[ng] / [ml],10,168947,DB00580,Valdecoxib
,12657846,Clearances,Clearances were reduced to 12% (0.64 +/- 0.25 ml. kg-1. min-1) and 61% (9.35 +/- 3.07) of control (5.53 +/- 2.16 and 15.3 +/- 5.0) for alfentanil and fentanyl (P < 0.001).,Simultaneous assessment of drug interactions with low- and high-extraction opioids: application to parecoxib effects on the pharmacokinetics and pharmacodynamics of fentanyl and alfentanil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12657846/),[ml] / [kg·min],0.64,176375,DB00580,Valdecoxib
,12657846,Clearances,Clearances were reduced to 12% (0.64 +/- 0.25 ml. kg-1. min-1) and 61% (9.35 +/- 3.07) of control (5.53 +/- 2.16 and 15.3 +/- 5.0) for alfentanil and fentanyl (P < 0.001).,Simultaneous assessment of drug interactions with low- and high-extraction opioids: application to parecoxib effects on the pharmacokinetics and pharmacodynamics of fentanyl and alfentanil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12657846/),,9.35,176376,DB00580,Valdecoxib
,12657846,Clearances,Clearances were reduced to 12% (0.64 +/- 0.25 ml. kg-1. min-1) and 61% (9.35 +/- 3.07) of control (5.53 +/- 2.16 and 15.3 +/- 5.0) for alfentanil and fentanyl (P < 0.001).,Simultaneous assessment of drug interactions with low- and high-extraction opioids: application to parecoxib effects on the pharmacokinetics and pharmacodynamics of fentanyl and alfentanil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12657846/),[ml] / [kg·min],5.53,176377,DB00580,Valdecoxib
,12657846,Clearances,Clearances were reduced to 12% (0.64 +/- 0.25 ml. kg-1. min-1) and 61% (9.35 +/- 3.07) of control (5.53 +/- 2.16 and 15.3 +/- 5.0) for alfentanil and fentanyl (P < 0.001).,Simultaneous assessment of drug interactions with low- and high-extraction opioids: application to parecoxib effects on the pharmacokinetics and pharmacodynamics of fentanyl and alfentanil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12657846/),[ml] / [kg·min],15.3,176378,DB00580,Valdecoxib
,27779354,V,"Parecoxib PK parameter estimates were CLPARECOXIB 19.1 L·h-1 ·70 kg-1 , V1PARECOXIB 4.2 L·70 kg-1 , Q2PARECOXIB 6.29 L·h-1 ·70 kg-1 , V2PARECOXIB 130 L·70 kg-1 , Q3PARECOXIB 6.02 L·h-1 ·70 kg-1 , and V3PARECOXIB 2.03 L·70 kg-1 .",Pharmacokinetics and analgesic effectiveness of intravenous parecoxib for tonsillectomy ± adenoidectomy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27779354/),[l] / [70·kg],4.2,178518,DB00580,Valdecoxib
,27779354,V2,"Parecoxib PK parameter estimates were CLPARECOXIB 19.1 L·h-1 ·70 kg-1 , V1PARECOXIB 4.2 L·70 kg-1 , Q2PARECOXIB 6.29 L·h-1 ·70 kg-1 , V2PARECOXIB 130 L·70 kg-1 , Q3PARECOXIB 6.02 L·h-1 ·70 kg-1 , and V3PARECOXIB 2.03 L·70 kg-1 .",Pharmacokinetics and analgesic effectiveness of intravenous parecoxib for tonsillectomy ± adenoidectomy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27779354/),[l] / [70·kg],130,178519,DB00580,Valdecoxib
,27779354,Q,"Parecoxib PK parameter estimates were CLPARECOXIB 19.1 L·h-1 ·70 kg-1 , V1PARECOXIB 4.2 L·70 kg-1 , Q2PARECOXIB 6.29 L·h-1 ·70 kg-1 , V2PARECOXIB 130 L·70 kg-1 , Q3PARECOXIB 6.02 L·h-1 ·70 kg-1 , and V3PARECOXIB 2.03 L·70 kg-1 .",Pharmacokinetics and analgesic effectiveness of intravenous parecoxib for tonsillectomy ± adenoidectomy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27779354/),[l] / [70·h·kg],6.02,178520,DB00580,Valdecoxib
,27779354,V,"Parecoxib PK parameter estimates were CLPARECOXIB 19.1 L·h-1 ·70 kg-1 , V1PARECOXIB 4.2 L·70 kg-1 , Q2PARECOXIB 6.29 L·h-1 ·70 kg-1 , V2PARECOXIB 130 L·70 kg-1 , Q3PARECOXIB 6.02 L·h-1 ·70 kg-1 , and V3PARECOXIB 2.03 L·70 kg-1 .",Pharmacokinetics and analgesic effectiveness of intravenous parecoxib for tonsillectomy ± adenoidectomy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27779354/),[l] / [70·kg],2.03,178521,DB00580,Valdecoxib
,12167567,terminal half-life,The estimated terminal half-life for valdecoxib was about 7 h.,"Disposition of a specific cyclooxygenase-2 inhibitor, valdecoxib, in human. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12167567/),h,7,190452,DB00580,Valdecoxib
,12642477,area under the curve from zero to infinity (AUC(0-infinity)),The plasma area under the curve from zero to infinity (AUC(0-infinity)) values for valdecoxib and M1 were 3.58 and 0.850 microg.,"Pharmacokinetics and metabolism of a COX-2 inhibitor, valdecoxib, in mice. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12642477/),μg,3.58,193444,DB00580,Valdecoxib
,12642477,area under the curve from zero to infinity (AUC(0-infinity)),The plasma area under the curve from zero to infinity (AUC(0-infinity)) values for valdecoxib and M1 were 3.58 and 0.850 microg.,"Pharmacokinetics and metabolism of a COX-2 inhibitor, valdecoxib, in mice. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12642477/),μg,0.850,193445,DB00580,Valdecoxib
,12642477,AUC(0-infinity),The RBC AUC(0-infinity) values for valdecoxib and M1 were 12.1 and 22.6 microg.,"Pharmacokinetics and metabolism of a COX-2 inhibitor, valdecoxib, in mice. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12642477/),μg,12.1,193446,DB00580,Valdecoxib
,12642477,AUC(0-infinity),The RBC AUC(0-infinity) values for valdecoxib and M1 were 12.1 and 22.6 microg.,"Pharmacokinetics and metabolism of a COX-2 inhibitor, valdecoxib, in mice. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12642477/),μg,22.6,193447,DB00580,Valdecoxib
,11583480,t(1/2),"Change in plasma concentrations of valdecoxib, which declined more slowly (t(1/2) = 5.4-9.9 hours), reflected transformation to several metabolites, one of which was the minor active metabolite M1.",A pharmacokinetic study of intramuscular (i.m.) parecoxib sodium in normal subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11583480/),h,5.4-9.9,218837,DB00580,Valdecoxib
,22130459,area under the curve (AUC) ratio,The parecoxib/valdecoxib area under the curve (AUC) ratio for both routes of administration was 1.4.,Pharmacokinetics of intravenous and intramuscular parecoxib in healthy Beagles. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22130459/),,1.4,235341,DB00580,Valdecoxib
,22130459,half-life,"The half-life of valdecoxib was about 2 h, which was shorter than reported for humans, although the plasma concentrations following both routes of administration were likely to be effective for analgesia.",Pharmacokinetics of intravenous and intramuscular parecoxib in healthy Beagles. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22130459/),h,2,235342,DB00580,Valdecoxib
,22130459,absolute bioavailability,The absolute bioavailability of parecoxib was 66%.,Pharmacokinetics of intravenous and intramuscular parecoxib in healthy Beagles. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22130459/),%,66,235343,DB00580,Valdecoxib
,22450476,Time to 50% maturation,Time to 50% maturation was 87 weeks postmenstrual age for both.,Development of a population pharmacokinetic model for parecoxib and its active metabolite valdecoxib after parenteral parecoxib administration in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22450476/),weeks,87,260099,DB00580,Valdecoxib
